AMSBIO has launched CancerSeq - a new range of genetically characterised FFPE tissue samples.
CancerSeq samples are prepared from genomic DNA extracted from the FFPE tumour tissues and validated by Next Generation Sequencing using Illumina’s TruSeq Amplicon - Cancer Panel (TSACP). Available as tissue slides and whole blocks, samples are delivered with the mutation and variation data for 48 cancer-related genes including BRAF, KRAS, EGFR, ALK and TP53.
CancerSeq tissue samples provide researchers with the perfect medium for applications including validation of cancer marker mutation related drug candidates ; companion diagnostic assay development ; cellular localization of tissue specific mRNA and protein expression ; Comparison of the locations of novel genes in different tissues as well as in situ hybridization, immunohistochemistry, and in situ PCR experiments.
Available from several tumour tissue types, donor clinical history data is provided with each CancerSeq sample. In addition - AMSBIO offers custom services to characterise your specimens or selected samples from its biorepository of cancer and normal FFPE blocks.
For more information, visit http://amsbio.com/Tissues-Paraffin-tissue-CancerSeq.aspx.
SOURCE: AMS Biotechnology (AMSBIO)